Rigosertib Completed Phase 1 Trials for Myelodysplastic Syndromes (MDS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00533416Safety of ON 01910.Na in Patients With Myelodysplasia